Biomarkers in Ovarian Pathology: From Screening to Diagnosis. Review of the Literature
Visualitza/
Impacte
Scholar |
Altres documents de l'autoria: Elorriaga, Miguel Ángel; Neyro, Jose Luis; Mieza, Jon; Cristóbal, Ignacio; Llueca, Antoni
Metadades
Mostra el registre complet de l'elementcomunitat-uji-handle:10234/9
comunitat-uji-handle2:10234/36080
comunitat-uji-handle3:10234/36082
comunitat-uji-handle4:
INVESTIGACIONMetadades
Títol
Biomarkers in Ovarian Pathology: From Screening to Diagnosis. Review of the LiteratureData de publicació
2021-10-29Editor
MDPIISSN
2075-4426Cita bibliogràfica
Elorriaga, M.Á.; Neyro, J.L.; Mieza, J.; Cristóbal, I.; Llueca, A. Biomarkers in Ovarian Pathology: From Screening to Diagnosis. Review of the Literature. J. Pers. Med. 2021, 11, 1115. https://doi.org/10.3390/ jpm11111115Tipus de document
info:eu-repo/semantics/articleVersió
info:eu-repo/semantics/publishedVersionParaules clau / Matèries
Resum
Background: Ovarian cancer has a low incidence, but high mortality due to a habitual diagnosis in advanced cancer stages. Currently, used biomarkers have good sensitivity, but low specificity.
Aim: To determine the ... [+]
Background: Ovarian cancer has a low incidence, but high mortality due to a habitual diagnosis in advanced cancer stages. Currently, used biomarkers have good sensitivity, but low specificity.
Aim: To determine the usefulness of the biomarkers and algorithms used up to now in the screening,
diagnosis, response to treatments and identification of recurrence in patients with ovarian masses.
Methodology: Systematic search of publications in English in the Medline-PubMed database with
the terms: “biomarkers”, “tumour”, “tumour biomarkers”, “marker”, “tumour marker”, “ovarian
cancer”, “ovarian”, “Neoplasms”, “cancer”, CA-125 Antigen; Human Epididymis-specific Protein
E4; Risk of Malignancy Index (RMI); Risk of Ovarian Malignancy Algorithm (ROMA); Ovarian
Neoplasms. Original articles, clinical trials, reviews, systematic reviews and meta-analyses, published between January 2000 and November 2020, were selected to determine the usefulness (among
others) of CA 125 and HE4 antigen in ovarian cancer. Results: Finally, 39 transcendental publications
were selected to write this article to determine the usefulness of tumour markers and algorithms in
ovarian cancer. Conclusions: The usefulness of the tumour markers antigen CA125 and antigen HE4
individually or as a basis for decision-making algorithms has low specificity; however, there is little
evidence that confirms their usefulness as markers in ovarian cancer screening [-]
Publicat a
Journal of Personalized Medicine, Vol. 11, Issue 11 (November 2021)Entitat finançadora
Medtronic University Chair for Training and Surgical Research, Universitat Jaume I = Cátedra Medtronic de Formación e Investigación quirúrgica de la Universitat Jaume I
Títol del projecte o subvenció
Drets d'accés
info:eu-repo/semantics/openAccess
Apareix a les col.leccions
- MED_Articles [639]
Except where otherwise noted, this item's license is described as Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).